Maturitas. 2010 May 21.
Effects of continuous combined hormone replacement therapy and clodronate on bone mineral density in osteoporotic postmenopausal women-A 5-year follow-up.
Tuppurainen M, Härmä K, Komulainen M, Kiviniemi V, Kröger H, Honkanen R, Alhava E, Jurvelin J, Saarikoski S.
Department of Obstetrics and Gynecology, Kuopio University Hospital, Kuopio, Finland; Bone and Cartilage Research Unit, Clinical Research Center, University of Eastern Finland, Kuopio, Finland.
OBJECTIVE: To determine the effects of HRT with or without clodronate on bone mineral density (BMD) change and bone turnover markers. DESIGN: Prospective, partly randomized trial. SETTING: Kuopio University Hospital, Finland. POPULATION: 167 osteoporotic women (61+/-2.7 years; T-score</=-2.5 SD). METHODS: Estradiol 2mg+NETA 1mg, randomization to additional 800mg clodronate (n=55, HT+C-group) or placebo (n=55, HT-group); if contraindications to HRT, clodronate (n=57, C-group). MAIN OUTCOME MEASURES: BMD by DXA after 1, 3 and 5 years, serum osteocalcin (OC) and bone-specific alkaline phosphatase (BAP) at the baseline and after 3 years. RESULTS: After 5 years, adjusted lumbar BMD increased by 4.2% in the HT-group and 3.7% in the HT+C-group. The C-group showed a decrease of -1.1%, the total difference being 5.3% and 4.8% between HT, HT+C vs. C-group, respectively (p<0.001). In the femoral neck, the adjusted 5-year BMD benefit was 1.3% and 2.4% in the HT- and HT+C-groups, respectively, the net loss of BMD in the C-group was -3.3% (p<0.05 between HT+C vs. C). By 3 years, OC decreased by 55.0%, 70.3% and 53.8% in the HT-, HT+C- and C-groups, respectively (p<0.001 vs. baseline). The significant decreases of BAP were 39.4% in the HT-group, 42.1% in the HT+C-group and 30.2% in the C-group with no significant differences between the groups after adjustments. CONCLUSIONS: In postmenopausal women with osteoporosis, HRT increased spinal and femoral BMD, but the combination of HRT and clodronate did not offer an extra gain of bone mass. Copyright © 2010. Published by Elsevier Ireland Ltd.
Effects of continuous combined hormone replacement therapy and clodronate on bone mineral density in osteoporotic postmenopausal women-A 5-year follow-up.
Tuppurainen M, Härmä K, Komulainen M, Kiviniemi V, Kröger H, Honkanen R, Alhava E, Jurvelin J, Saarikoski S.
Department of Obstetrics and Gynecology, Kuopio University Hospital, Kuopio, Finland; Bone and Cartilage Research Unit, Clinical Research Center, University of Eastern Finland, Kuopio, Finland.
OBJECTIVE: To determine the effects of HRT with or without clodronate on bone mineral density (BMD) change and bone turnover markers. DESIGN: Prospective, partly randomized trial. SETTING: Kuopio University Hospital, Finland. POPULATION: 167 osteoporotic women (61+/-2.7 years; T-score</=-2.5 SD). METHODS: Estradiol 2mg+NETA 1mg, randomization to additional 800mg clodronate (n=55, HT+C-group) or placebo (n=55, HT-group); if contraindications to HRT, clodronate (n=57, C-group). MAIN OUTCOME MEASURES: BMD by DXA after 1, 3 and 5 years, serum osteocalcin (OC) and bone-specific alkaline phosphatase (BAP) at the baseline and after 3 years. RESULTS: After 5 years, adjusted lumbar BMD increased by 4.2% in the HT-group and 3.7% in the HT+C-group. The C-group showed a decrease of -1.1%, the total difference being 5.3% and 4.8% between HT, HT+C vs. C-group, respectively (p<0.001). In the femoral neck, the adjusted 5-year BMD benefit was 1.3% and 2.4% in the HT- and HT+C-groups, respectively, the net loss of BMD in the C-group was -3.3% (p<0.05 between HT+C vs. C). By 3 years, OC decreased by 55.0%, 70.3% and 53.8% in the HT-, HT+C- and C-groups, respectively (p<0.001 vs. baseline). The significant decreases of BAP were 39.4% in the HT-group, 42.1% in the HT+C-group and 30.2% in the C-group with no significant differences between the groups after adjustments. CONCLUSIONS: In postmenopausal women with osteoporosis, HRT increased spinal and femoral BMD, but the combination of HRT and clodronate did not offer an extra gain of bone mass. Copyright © 2010. Published by Elsevier Ireland Ltd.
Facebook's Most Popular Menopause Doctor
Georgianna, 50
Medical Office Manager
Arcadia, CA
Medical Office Manager
Arcadia, CA
"It's wonderful having Dr. Miller in town. When I refer my patients to her I know they will receive both outstanding medical care and VIP treatment."
Dr. Bijan Pourat
Cardiologist
Beverly Hills, CA
Click here
to listen to Dr. Miller on 1480 KYOS.
Click here
to listen to Dr. Miller on 88.9 KRFC. NEW!
Disclaimer: All the information on this website is intended for educational purposes only, and should not be construed as personal medical advice. Dr. Miller encourages you to do your research and make your own health care decisions with the guidance of a qualified physician.
Contact
Dr. Shira Miller, The Integrative Center for Health & Wellness
562 S. San Vicente Blvd.
Los Angeles, CA 90048
Get Directions
562 S. San Vicente Blvd.
Los Angeles, CA 90048
Get Directions
- Phone: 310-734-8864
- Fax: 310-943-6345
- Email Us